HCPLive Network
PRACTICE MANAGEMENT

Roundtable: To Sell or Not to Sell, Part III

| Friday, November 15, 2013
Moderator:
Lee Ferber, CFP
Marcus Gettry, CPA, P.C.
David Mandell
OJM Group, LLC
Principal
Todd Rodriguez
Fox Rothschild
Partner, Health Law Practice


In this roundtable, panelists will discuss analyzing whether a practice should stay private or sell to a hospital and Todd Rodriguez, partner with Fox Rothschild, explained specific terms embedded in hospital employment agreements. He looks specifically for things, such as grounds for termination and productivity targets, in the contract that might be beyond the control of the physician
 
In particular, he views the most important part of the contract for physicians who are leaving private practice is the ability to return to private practice.
 
“If you get into the arrangement and decide it’s not your cup of tea or it’s not working out for whatever reason, you at least can go back to the status quo,” Rodriguez said. “That’s a fairly big protection.”



Part 1 | Part 2 | Part 4 | Part 5

RELATED ARTICLES
The term “venture capitalist” has been bannered across all media for years now, but most folks outside that cloistered sub-culture here in Silicon Valley know little about it.
There have been quite a few hot IPOs this year. Alibaba and GoPro to name just a couple. But the real money was made before these companies even went public.
As the name suggests, Robo-advisors are not going to provide warm and fuzzy service like the human advisors to which investors are accustomed. But, Robos are less expensive, which brings up this question, “Can investors give up the good feelings a mortal imparts in exchange for paying less?”
RECENT CLINICAL ARTICLES
Complication rates are similar for single-level anterior cervical discectomy and fusions, whether the procedure is performed by a neurosurgeon or orthopedic surgeon, according to a study published in the Sept. 15 issue of Spine.
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.